查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701807

2025 年至 2033 年疫苗市场报告（按技术、患者类型、适应症、给药途径、产品类型、治疗类型、最终用户、配销通路和地区划分）

Vaccine Market Report by Technology, Patient Type, Indication, Route of Administration, Product Type, Treatment Type, End User, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

2024年全球疫苗市场规模达598亿美元。展望未来， IMARC Group预计到2033年市场规模将达到1,365亿美元，2025-2033年期间的成长率（CAGR）为9.12%。推动个人接种疫苗的严格法规的实施、生物技术和疫苗开发技术的若干进步以及民众对疫苗接种重要性的日益增强的健康意识是推动市场发展的一些主要因素。

疫苗是公共卫生的重要工具，旨在预防和控制传染病的传播。它们本质上是刺激免疫系统识别和对抗特定病原体（如细菌或病毒）的生物製剂。它们含有目标病原体的弱化或灭活形式或其片段，称为抗原。接种疫苗时，疫苗会模拟感染，促使免疫系统产生抗体并形成免疫记忆。此外，当个体接触到实际病原体时，它能确保免疫系统迅速发动防御，有效预防疾病或减轻其严重程度。

市场的主要驱动力是人们日益增长的健康问题。此外，最近爆发的冠状病毒病（COVID-19）疫情提高了人们对产品在维护公共健康方面的重要性的认识，从而促进了市场的成长。此外，mRNA 产品等新型疫苗技术的开发正在透过提供更快、更精确的疫苗开发能力来改变整个产业，有效应对新出现的威胁，从而成为另一个主要的成长诱因。除此之外，製药公司正在扩大其疫苗组合，包括针对传统疾病以外的各种疾病的疫苗，从而开闢了新的市场和收入来源，从而加速了销售需求。除此之外，政府采取的多项倡议，包括疫苗接种运动、公众意识宣传活动以及为遏制疾病传播而提供的疫苗研究资金，正在推动市场成长。此外，公共和私营部门正在进行的疫苗研发投资（R&D）确保了新产品的强劲供应，从而创造了积极的市场前景。

疫苗市场趋势/驱动因素：

实施严格的法规，促进接种疫苗

该市场受到旨在促进个人接种疫苗的严格法规的实施所推动。此外，对疫苗安全性和有效性的日益重视也促进了市场的成长。此外，製造商坚持严格的测试和品质控制措施，以确保产品符合最高的安全标准，从而增加对研发（R&D）的投资，以创造出有效预防疾病且副作用最小的产品，从而成为另一个主要的成长诱导因素。除此之外，该公司还提供有关其产品的清晰全面的信息，包括潜在的副作用和禁忌症，使个人能够对疫苗接种做出明智的决定，从而加快产品采用率。除此之外，各国政府和医疗机构正在实施各种激励计划，包括补贴、公众意识宣传活动，在某些情况下还鼓励接种疫苗，从而推动市场成长。

生物技术和疫苗开发技术的多项进展

生物技术和疫苗开发技术的几项显着进步推动了市场的发展。它正在改变疫苗的设计和製造方式，有助于开发高效、有针对性的疫苗。此外，基因组学和分子生物学在疫苗开发中的应用使科学家能够以前所未有的速度和精度解码病原体的遗传讯息，使他们能够更有效地识别潜在的候选疫苗，从而开发出针对 COVID-19 等新兴疾病的产品，从而促进了市场的成长。此外，重组脱氧核糖核酸（DNA）技术的几项进步使得重组疫苗的产生成为可能，这种疫苗可以在不引起疾病本身的情况下刺激增强的免疫反应，从而有效预防包括乙肝和人类乳头瘤病毒在内的传染病，从而成为另一个主要的经济成长诱因。此外，合成生物学技术的应用也促进了多项创新，使科学家能够精确设计和合成疫苗成分，以开发针对挑战性病原体的新型疫苗，从而创造积极的市场前景。

人们越来越意识到疫苗接种的重要性

市场的发展受到人们日益增强的健康意识（对疫苗接种的重要性的认识）的推动。此外，最近爆发的冠状病毒病 (COVID-19) 疫情提高了公众对疫苗接种价值的认识，从而促进了市场的成长。同时，製造商正在开发和分发疫苗对抗病毒，同时专注于疫苗的有效性、安全性和可及性，从而推动市场成长。此外，透过医疗保健提供者、政府机构和媒体等各种管道传播准确的资讯以保障公众健康，这是另一个重要的成长诱因。除此之外，社群媒体和数位平台的兴起在提供疫苗接种资讯方面发挥了重要作用，使个人能够获得可靠的资源并参与知情讨论。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势
    • 监管格局
      • 美国
      • 加拿大
      • 欧洲联盟
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲
      • 俄罗斯
      • 巴西
      • 墨西哥
      • 土耳其
      • 海湾合作委员会国家
      • 以色列
    • 新疫苗产品线
      • HIV产品线
      • 寨卡病毒产品线
      • 伊波拉病毒产品线
      • COVID-19 产品线

第五章：全球疫苗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依技术

  • 结合疫苗
  • 灭活疫苗和次单位疫苗
  • 减毒活疫苗
  • 重组疫苗
  • 类毒素疫苗
  • 其他的

第七章：市场区隔：依患者类型

  • 儿科
  • 成人

第八章：市场区隔：依指标

  • 细菌性疾病
    • 主要类型
      • 脑膜炎球菌疾病
      • 肺炎球菌疾病
      • 白喉/破伤风/百日咳（DPT）
      • 结核
      • 流感嗜血桿菌（Hib）
      • 伤寒
      • 其他的
  • 病毒性疾病
    • 主要类型
      • 肝炎
      • 流感
      • 人类乳突病毒（HPV）
      • 麻疹/腮腺炎/德国麻疹 (MMR)
      • 轮状病毒
      • 带状疱疹
      • 水痘
      • 日本脑炎
      • 风疹
      • 小儿麻痹
      • 狂犬病
      • 登革热
      • 其他的

第九章：市场细分：依行政途径

  • 肌肉注射和皮下注射
  • 口服
  • 其他的

第十章：市场区隔：依产品类型

  • 多价疫苗
  • 单价疫苗

第 11 章：市场区隔：依治疗类型

  • 预防疫苗
  • 治疗性疫苗

第 12 章：市场区隔：依最终用户

  • 医院
  • 诊所
  • 疫苗接种中心
  • 学术和研究机构
  • 其他的

第十三章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 机构销售
  • 其他的

第 14 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 土耳其
    • 海湾合作委员会国家
    • 以色列
    • 其他的

第 15 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 16 章：价值链分析

  • 探索阶段
  • 临床前和临床开发
  • 监管部门批准
  • 製造业
  • 行销与分销

第 17 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 18 章：价格分析

第十九章：主要驱动因素与挑战

第 20 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bharat Biotech International
    • Bavarian Nordic A/S
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline Plc
    • Inovio Pharmaceuticals Inc.
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
    • Novavax Inc.
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi Pasteur SA (Sanofi SA)
    • Serum Institute of India Pvt. Ltd.
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A2374

The global vaccine market size reached USD 59.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 136.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.12% during 2025-2033. The implementation of stringent regulations promoting the adoption of vaccination among individuals, several advances in biotechnology and vaccine development techniques, and the growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.

Vaccines are essential tools in public health, designed to prevent and control the spread of infectious diseases. They are essentially biological preparations that stimulate the immune system to recognize and fight specific pathogens, such as bacteria or viruses. They contain weakened or inactivated forms of the target pathogen or pieces of it, known as antigens. When administered, vaccination mimic an infection, prompting the immune system to produce antibodies and develop immune memory. Additionally, it ensures immune system to swiftly mount a defense, effectively preventing illness or reducing its severity, when the individual is exposed to the actual pathogen.

The market is primarily driven by the growing health concerns among individuals. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised awareness among individuals regarding the importance of the product in safeguarding public health, thus augmenting the market growth. Moreover, the development of novel vaccine technologies, such as mRNA products are transforming the industry by offering faster and precise vaccine development capabilities, addressing emerging threats effectively, thus representing another major growth-inducing factor. Besides this, pharmaceutical companies are expanding their vaccine portfolios to include vaccinations for various diseases beyond the traditional ones which opened new markets and revenue streams, thus accelerating the sales demand. Along with this, several government initiatives including vaccination drives, public awareness campaigns, and funding for vaccine research to curb the spread of diseases are propelling the market growth. Furthermore, the ongoing vaccine research and development investment (R&D) in public and private sectors ensures a robust pipeline of new products, thus creating a positive market outlook.

Vaccine Market Trends/Drivers:

The implementation of stringent regulations promoting the adoption of vaccination

The market is driven by the enforcement of stringent regulations aimed at promoting vaccination among individuals. In addition, the growing emphasis on vaccine safety and efficacy is augmenting the market growth. Moreover, manufacturers adhere to rigorous testing and quality control measures to ensure that products meet the highest standards of safety, resulting in rising investment in research and development (R&D) to create products that prevent diseases effectively and have minimal adverse effects, thus representing another major growth-inducing factor. Besides this, companies are providing clear and comprehensive information about their products, including potential side effects and contraindications which empowers individuals to make informed decisions about vaccination, thus accelerating the product adoption rate. Along with this, various governments and healthcare authorities are implementing various incentive programs including subsidies, public awareness campaigns, and mandates in some cases encouraging the adoption of vaccination, thus propelling the market growth.

Several advances in biotechnology and vaccine development techniques

The market is driven by several remarkable advances in biotechnology and vaccine development techniques. It is transforming the way vaccinations are designed and manufactured which is contributing to the development of highly effective and targeted vaccinations. In addition, the utilization of genomics and molecular biology in vaccine development led scientists to decode the genetic information of pathogens with unprecedented speed and precision, enabling them to identify potential vaccine candidates more efficiently, resulting in the development of products against emerging diseases such as COVID-19, thus augmenting the market growth. Moreover, several advancements in recombinant deoxyribonucleic acid (DNA) technology allowed for the creation of recombinant vaccinations, stimulating enhanced immune response without causing the disease itself which is effective in preventing infectious diseases, including hepatitis B and human papillomavirus, thus representing another major growth-induing factor. Furthermore, the application of synthetic biology techniques is also contributing to several innovations, allowing scientists to design and synthesize vaccine components with precision, for the development of novel vaccinations against challenging pathogens, thus creating a positive market outlook.

The growing awareness about the importance of vaccination

The market is driven by the growing health awareness among individuals regarding the importance of vaccination. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised public awareness about the value of vaccination, thus augmenting the market growth. Along with this, manufacturers are developing and distributing vaccinations to combat the virus while focusing on vaccine efficacy, safety, and accessibility, thus propelling the market growth. Moreover, the dissemination of accurate information through various channels, including healthcare providers, government agencies, and the media to safeguard public health, which represents another major growth-inducing factor. Besides this, the rise of social media and digital platforms played a significant part in providing information about vaccinations, enabling individuals to access reliable resources and engage in informed discussions.

Vaccine Industry Segmentation:

Breakup by Technology:

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
  • Others

Conjugate products are gaining popularity due to their effectiveness in preventing bacterial infections. They are designed to elicit a strong immune response and are particularly used for diseases such as haemophilus influenzae type B (Hib) and streptococcus pneumoniae.

Moreover, inactivated and subunit products are widely used for viral diseases, such as influenza, hepatitis B, and human papillomavirus (HPV) which contain components of the pathogen, ensuring safety while still providing immunity, thus representing another major growth-inducing factor. Besides this, Live attenuated vaccines are created from weakened forms of pathogens and are effective against diseases such as measles, mumps, and rubella which are essential in disease eradication programs, thus accelerating the sales demand.

Along with this, recombinant products use genetic engineering to create vaccinations against diseases such as hepatitis B and human papillomavirus and offer potential for customization and efficacy, thus propelling the market growth. Also, toxoid vaccinations are employed for bacterial diseases including diphtheria and tetanus due to their long-lasting immunity benefits, thus augmenting the market growth.

Breakup by Patient Type:

  • Pediatric
  • Adult

Pediatric patients hold the largest share of the market

The pediatrics segment is driven by the growing emphasis on immunization, thus influencing the market growth. Moreover, governments and healthcare organizations are preventing childhood diseases, leading to increasing vaccination programs and investments in pediatric vaccine research, thus contributing to market growth.

Moreover, several advancements in vaccine technology made it possible to develop safer and more effective vaccinations for children, resulting in a steady stream of new vaccinations tailored specifically for pediatric populations, representing another major growth-inducing factor.

Additionally, the COVID-19 pandemic underscored the importance of vaccinations for children. Efforts to vaccinate children against the virus further increase the role of pediatrics in the vaccine industry, thus propelling the market growth.

Breakup by Indication:

  • Bacterial Diseases
    • Meningococcal Disease
    • Pneumococcal Disease
    • Diphtheria/Tetanus/Pertussis (DPT)
    • Tuberculosis
    • Haemophilus Influenzae (Hib)
    • Typhoid
    • Others
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus (HPV)
    • Measles/Mumps/Rubella (MMR)
    • Rotavirus
    • Herpes Zoster
    • Varicella
    • Japanese Encephalitis
    • Rubella
    • Polio
    • Rabies
    • Dengue
    • Others

Bacterial diseases presently account for the largest market share

The market is driven by the growing incidences of bacterial diseases, caused by various bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. In addition, the increasing development of effective vaccinations to prevent these infections is augmenting the market growth.

Furthermore, several advancements in vaccine technology are improving bacterial disease vaccinations. Along with this, several innovations in research and development (R&D) yielded vaccinations that are effective and safe for widespread use which are designed to stimulate the body's immune response, thereby conferring immunity against bacterial pathogens, thus propelling the market growth.

Breakup by Route of Administration:

  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Others

Intramuscular and subcutaneous administration represents the leading segment

Intramuscular administration involves injecting vaccinations directly into the muscle tissue which offers several advantages. In addition, muscles have an abundant blood supply, allowing for efficient uptake and distribution of the vaccine components leading to improved immune response, thus influencing the market growth. Along with this, IM injections often require larger needles, which can facilitate the administration of vaccinations with thicker formulations or those containing adjuvants, thus augmenting the market growth.

Moreover, subcutaneous administration involves injecting vaccinations into the fatty tissue just beneath the skin which is preferred for products that are well-suited for slower, sustained release into the bloodstream, thus representing another major growth-inducing factor. It is less invasive and typically uses smaller needles, making it a preferred choice among individuals who may be apprehensive about needles.

Breakup by Product Type:

  • Multivalent Vaccine
  • Monovalent Vaccine

Multivalent vaccine represent the most used product type

Multivalent offers a streamlined approach to immunization by combining antigens from different pathogens into a single vaccine, which reduces the number of injections required, minimizing discomfort for patients and simplifying vaccination schedules, thus augmenting the market growth.

Furthermore, multivalent vaccinations are efficient in preventing several diseases. For instance, combination vaccinations such as the measles, mumps, and rubella (MMR) vaccinations are eliminating these diseases in many regions, resulting in extensive research and development (R&D) efforts in the field, thus propelling the market growth.

Along with this, multivalent vaccinations offer substantial advantages, as the production, distribution, and administration of a single vaccine covering multiple diseases are more efficient and economical compared to individual vaccinations for each pathogen, thus accelerating the product adoption rate among healthcare systems and patients.

Breakup by Treatment Type:

  • Preventive Vaccine
  • Therapeutic Vaccine

Preventive vaccine currently dominates the market

Preventive vaccinations are designed to proactively protect individuals from contracting specific diseases. They achieve this by stimulating the immune system to produce antibodies that recognize and neutralize pathogens, such as viruses or bacteria, should the individual be exposed to them in the future has proven to be highly effective in reducing the incidence and severity of various illnesses.

Moreover, it has immense success in eradicating or controlling life-threatening diseases. Some historical examples include the near-eradication of smallpox through vaccination and the significant reduction in polio cases which are essential in fighting against infectious diseases. Furthermore, the rapid development and distribution of products to combat the virus and save countless lives are propelling the market growth.

Breakup by End User:

  • Hospitals
  • Clinics
  • Vaccination Centers
  • Academic and Research Institutes
  • Others

Hospitals hold the largest share of the market

The hospital industry is driven by its strategic position as a primary healthcare provider. In addition, hospitals serve as the frontline of defense against infectious diseases, making them the ideal setting for vaccine dissemination which possesses the necessary infrastructure, medical personnel, and resources to efficiently handle the storage, distribution, and administration of products, thus propelling the market growth.

Furthermore, hospitals are essential in vaccination advocacy and education. They are trusted sources of healthcare information, and their healthcare professionals serve as product advocates through patient consultations, seminars, and informational campaigns. Along with this, hospitals are promoting the importance of vaccination, contributing to higher vaccination rates and public awareness.

Along with this, hospitals also engage in product research and development (R&D), partnering with pharmaceutical companies and research institutions to conduct clinical trials and assess vaccination efficacy, thus contributing to market growth.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Hospital pharmacies presently account for the largest market share

Hospital pharmacies are located at the heart of healthcare facilities which ensures that vaccinations are easily accessible to healthcare professionals and patients. Hospitals are often the first point of contact for individuals seeking vaccination, whether it's for routine immunizations or during public health emergencies.

Moreover, hospital pharmacies have the infrastructure and trained staff necessary to handle and administer products safely while adhering to strict quality control and storage protocols, ensuring the integrity and efficacy of vaccinations throughout the distribution process, thus representing another major growth-inducing factor. This reliability and commitment to maintaining the cold chain are essential for preserving the potency of products.

Along with this, hospital pharmacies benefit from established relationships with healthcare providers and government agencies responsible for vaccination programs which allows for seamless coordination in vaccination procurement, distribution, and administration, thus propelling the market growth. Also, hospitals serve as vaccination hubs during mass immunization campaigns, further solidifying their role in the market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
    • Turkey
    • GCC Countries
    • Israel
    • Others

Asia Pacific exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.

The Asia Pacific market is driven by the growing pharmaceutical and biotechnology sector. In addition, several countries such as India and China are investing heavily in the development of their healthcare infrastructure, research capabilities, and manufacturing capacities, allowing them to produce vaccination at scale, often at a lower cost than their Western counterparts. thus, contributing to the market growth.

Additionally, the rising pool of skilled scientists, researchers, and healthcare professionals is augmenting the market growth. These experts are driving innovation and ensuring the quality and safety of vaccinations produced in the region. Furthermore, the region offers ample opportunities for clinical trials and testing, allowing for the accelerated development of new products, thus accelerating the sales demand.

Apart from this, the strategic partnerships and collaborations among pharmaceutical companies in the region are facilitating technology transfer, knowledge sharing, and access to critical resources, strengthening the region's position in the market.

Competitive Landscape:

At present, key players in the market are taking strategic initiatives to strengthen their positions in the competitive landscape of the market research and consulting services industry. These actions are vital for maintaining their relevance and authority in the field. They are embracing advanced technologies including artificial intelligence, machine learning, and data analytics which help in delivering more accurate and actionable insights, that is highly valued by clients. Moreover, companies are establishing thought leadership through content marketing and thought-provoking research reports which help in showcasing expertise and attract clients who seek industry insights. Besides this, they are focusing on client satisfaction and building long-term relationships by providing personalized services and tailored solutions based on client requirements that enhance trust and loyalty.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bharat Biotech International
  • Bavarian Nordic A/S
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
  • Novavax Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur SA (Sanofi SA)
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited.

Recent Developments:

  • In September 2020, the Serum Institute of India Pvt. Ltd., partnered with Gavi and the Bill & Melinda Gates Foundation to accelerate the production and distribution of an additional 100 million doses of COVID-19 vaccines that are safe and effective.
  • In April 2023, Pfizer Inc., announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.
  • In June 2022, GlaxoSmithKline Plc officially submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (USFDA) for their experimental vaccine known as PRIORIX, which originally registered in Germany, has received licenses from more than 100 countries.

Key Questions Answered in This Report

  • 1.What was the size of the global vaccine market in 2024?
  • 2.What is the expected growth rate of the global vaccine market during 2025-2033?
  • 3.What are the key factors driving the global vaccine market?
  • 4.What has been the impact of COVID-19 on the global vaccine market?
  • 5.What is the breakup of the global vaccine market based on the patient type?
  • 6.What is the breakup of the global vaccine market based on the indication?
  • 7.What is the breakup of the global vaccine market based on the route of administration?
  • 8.What is the breakup of the global vaccine market based on the product type?
  • 9.What is the breakup of the global vaccine market based on the treatment type?
  • 10.What is the breakup of the global vaccine market based on the end user?
  • 11.What is the breakup of the global vaccine market based on the distribution channel?
  • 12.What are the key regions in the global vaccine market?
  • 13.Who are the key players/companies in the global vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends
    • 4.2.1 Regulatory Landscape
      • 4.2.1.1 United States
      • 4.2.1.2 Canada
      • 4.2.1.3 European Union
      • 4.2.1.4 China
      • 4.2.1.5 India
      • 4.2.1.6 Japan
      • 4.2.1.7 South Korea
      • 4.2.1.8 Australia
      • 4.2.1.9 Russia
      • 4.2.1.10 Brazil
      • 4.2.1.11 Mexico
      • 4.2.1.12 Turkey
      • 4.2.1.13 GCC Countries
      • 4.2.1.14 Israel
    • 4.2.2 Product Pipeline for New Vaccines
      • 4.2.2.1 Product Pipeline for HIV
      • 4.2.2.2 Product Pipeline for Zika Virus
      • 4.2.2.3 Product Pipeline for Ebola Virus
      • 4.2.2.4 Product Pipeline for COVID-19

5 Global Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Conjugate Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated and Subunit Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Live Attenuated Vaccines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Recombinant Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Toxoid Vaccines
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Patient Type

  • 7.1 Paediatric
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Adult
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Bacterial Diseases
    • 8.1.1 Market Trends
    • 8.1.2 Major Types
      • 8.1.2.1 Meningococcal Disease
        • 8.1.2.1.1 Market Trends
        • 8.1.2.1.2 Market Forecast
      • 8.1.2.2 Pneumococcal Disease
        • 8.1.2.2.1 Market Trends
        • 8.1.2.2.2 Market Forecast
      • 8.1.2.3 Diphtheria/Tetanus/Pertussis (DPT)
        • 8.1.2.3.1 Market Trends
        • 8.1.2.3.2 Market Forecast
      • 8.1.2.4 Tuberculosis
        • 8.1.2.4.1 Market Trends
        • 8.1.2.4.2 Market Forecast
      • 8.1.2.5 Haemophilus Influenzae (Hib)
        • 8.1.2.5.1 Market Trends
        • 8.1.2.5.2 Market Forecast
      • 8.1.2.6 Typhoid
        • 8.1.2.6.1 Market Trends
        • 8.1.2.6.2 Market Forecast
      • 8.1.2.7 Others
        • 8.1.2.7.1 Market Trends
        • 8.1.2.7.2 Market Forecast
    • 8.1.3 Market Forecast
  • 8.2 Viral Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Major Types
      • 8.2.2.1 Hepatitis
        • 8.2.2.1.1 Market Trends
        • 8.2.2.1.2 Market Forecast
      • 8.2.2.2 Influenza
        • 8.2.2.2.1 Market Trends
        • 8.2.2.2.2 Market Forecast
      • 8.2.2.3 Human Papillomavirus (HPV)
        • 8.2.2.3.1 Market Trends
        • 8.2.2.3.2 Market Forecast
      • 8.2.2.4 Measles/Mumps/Rubella (MMR)
        • 8.2.2.4.1 Market Trends
        • 8.2.2.4.2 Market Forecast
      • 8.2.2.5 Rotavirus
        • 8.2.2.5.1 Market Trends
        • 8.2.2.5.2 Market Forecast
      • 8.2.2.6 Herpes Zoster
        • 8.2.2.6.1 Market Trends
        • 8.2.2.6.2 Market Forecast
      • 8.2.2.7 Varicella
        • 8.2.2.7.1 Market Trends
        • 8.2.2.7.2 Market Forecast
      • 8.2.2.8 Japanese Encephalitis
        • 8.2.2.8.1 Market Trends
        • 8.2.2.8.2 Market Forecast
      • 8.2.2.9 Rubella
        • 8.2.2.9.1 Market Trends
        • 8.2.2.9.2 Market Forecast
      • 8.2.2.10 Polio
        • 8.2.2.10.1 Market Trends
        • 8.2.2.10.2 Market Forecast
      • 8.2.2.11 Rabies
        • 8.2.2.11.1 Market Trends
        • 8.2.2.11.2 Market Forecast
      • 8.2.2.12 Dengue
        • 8.2.2.12.1 Market Trends
        • 8.2.2.12.2 Market Forecast
      • 8.2.2.13 Others
        • 8.2.2.13.1 Market Trends
        • 8.2.2.13.2 Market Forecast
    • 8.2.3 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Intramuscular and Subcutaneous Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Product Type

  • 10.1 Multivalent Vaccine
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Monovalent Vaccine
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Treatment Type

  • 11.1 Preventive Vaccine
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Therapeutic Vaccine
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast

12 Market Breakup by End User

  • 12.1 Hospitals
    • 12.1.1 Market Trends
    • 12.1.2 Market Forecast
  • 12.2 Clinics
    • 12.2.1 Market Trends
    • 12.2.2 Market Forecast
  • 12.3 Vaccination Centres
    • 12.3.1 Market Trends
    • 12.3.2 Market Forecast
  • 12.4 Academic and Research Institutes
    • 12.4.1 Market Trends
    • 12.4.2 Market Forecast
  • 12.5 Others
    • 12.5.1 Market Trends
    • 12.5.2 Market Forecast

13 Market Breakup by Distribution Channel

  • 13.1 Hospital Pharmacies
    • 13.1.1 Market Trends
    • 13.1.2 Market Forecast
  • 13.2 Retail Pharmacies
    • 13.2.1 Market Trends
    • 13.2.2 Market Forecast
  • 13.3 Institutional Sales
    • 13.3.1 Market Trends
    • 13.3.2 Market Forecast
  • 13.4 Others
    • 13.4.1 Market Trends
    • 13.4.2 Market Forecast

14 Market Breakup by Region

  • 14.1 North America
    • 14.1.1 United States
      • 14.1.1.1 Market Trends
      • 14.1.1.2 Market Forecast
    • 14.1.2 Canada
      • 14.1.2.1 Market Trends
      • 14.1.2.2 Market Forecast
  • 14.2 Asia Pacific
    • 14.2.1 China
      • 14.2.1.1 Market Trends
      • 14.2.1.2 Market Forecast
    • 14.2.2 Japan
      • 14.2.2.1 Market Trends
      • 14.2.2.2 Market Forecast
    • 14.2.3 India
      • 14.2.3.1 Market Trends
      • 14.2.3.2 Market Forecast
    • 14.2.4 South Korea
      • 14.2.4.1 Market Trends
      • 14.2.4.2 Market Forecast
    • 14.2.5 Australia
      • 14.2.5.1 Market Trends
      • 14.2.5.2 Market Forecast
    • 14.2.6 Others
      • 14.2.6.1 Market Trends
      • 14.2.6.2 Market Forecast
  • 14.3 Europe
    • 14.3.1 Germany
      • 14.3.1.1 Market Trends
      • 14.3.1.2 Market Forecast
    • 14.3.2 France
      • 14.3.2.1 Market Trends
      • 14.3.2.2 Market Forecast
    • 14.3.3 United Kingdom
      • 14.3.3.1 Market Trends
      • 14.3.3.2 Market Forecast
    • 14.3.4 Italy
      • 14.3.4.1 Market Trends
      • 14.3.4.2 Market Forecast
    • 14.3.5 Spain
      • 14.3.5.1 Market Trends
      • 14.3.5.2 Market Forecast
    • 14.3.6 Russia
      • 14.3.6.1 Market Trends
      • 14.3.6.2 Market Forecast
    • 14.3.7 Others
      • 14.3.7.1 Market Trends
      • 14.3.7.2 Market Forecast
  • 14.4 Latin America
    • 14.4.1 Brazil
      • 14.4.1.1 Market Trends
      • 14.4.1.2 Market Forecast
    • 14.4.2 Mexico
      • 14.4.2.1 Market Trends
      • 14.4.2.2 Market Forecast
    • 14.4.3 Others
      • 14.4.3.1 Market Trends
      • 14.4.3.2 Market Forecast
  • 14.5 Middle East and Africa
    • 14.5.1 Turkey
      • 14.5.1.1 Market Trends
      • 14.5.1.2 Market Forecast
    • 14.5.2 GCC Countries
      • 14.5.2.1 Market Trends
      • 14.5.2.2 Market Forecast
    • 14.5.3 Israel
      • 14.5.3.1 Market Trends
      • 14.5.3.2 Market Forecast
    • 14.5.4 Others
      • 14.5.4.1 Market Trends
      • 14.5.4.2 Market Forecast

15 SWOT Analysis

  • 15.1 Overview
  • 15.2 Strengths
  • 15.3 Weaknesses
  • 15.4 Opportunities
  • 15.5 Threats

16 Value Chain Analysis

  • 16.1 Exploratory Stage
  • 16.2 Preclinical and Clinical Development
  • 16.3 Regulatory Approval
  • 16.4 Manufacturing
  • 16.5 Marketing and Distribution

17 Porters Five Forces Analysis

  • 17.1 Overview
  • 17.2 Bargaining Power of Buyers
  • 17.3 Bargaining Power of Suppliers
  • 17.4 Degree of Competition
  • 17.5 Threat of New Entrants
  • 17.6 Threat of Substitutes

18 Price Analysis

19 Major Drivers and Challenges

20 Competitive Landscape

  • 20.1 Market Structure
  • 20.2 Key Players
  • 20.3 Profiles of Key Players
    • 20.3.1 Abbott Laboratories
      • 20.3.1.1 Company Overview
      • 20.3.1.2 Product Portfolio
      • 20.3.1.3 Financials
      • 20.3.1.4 SWOT Analysis
    • 20.3.2 Astellas Pharma Inc.
      • 20.3.2.1 Company Overview
      • 20.3.2.2 Product Portfolio
      • 20.3.2.3 Financials
      • 20.3.2.4 SWOT Analysis
    • 20.3.3 AstraZeneca Plc
      • 20.3.3.1 Company Overview
      • 20.3.3.2 Product Portfolio
      • 20.3.3.3 Financials
      • 20.3.3.4 SWOT Analysis
    • 20.3.4 Bharat Biotech International
      • 20.3.4.1 Company Overview
      • 20.3.4.2 Product Portfolio
    • 20.3.5 Bavarian Nordic A/S
      • 20.3.5.1 Company Overview
      • 20.3.5.2 Product Portfolio
      • 20.3.5.3 Financials
    • 20.3.6 CSL Limited
      • 20.3.6.1 Company Overview
      • 20.3.6.2 Product Portfolio
      • 20.3.6.3 Financials
      • 20.3.6.4 SWOT Analysis
    • 20.3.7 Daiichi Sankyo Company Limited
      • 20.3.7.1 Company Overview
      • 20.3.7.2 Product Portfolio
    • 20.3.8 Emergent BioSolutions Inc.
      • 20.3.8.1 Company Overview
      • 20.3.8.2 Product Portfolio
      • 20.3.8.3 Financials
      • 20.3.8.4 SWOT Analysis
    • 20.3.9 GlaxoSmithKline Plc
      • 20.3.9.1 Company Overview
      • 20.3.9.2 Product Portfolio
      • 20.3.9.3 Financials
      • 20.3.9.4 SWOT Analysis
    • 20.3.10 Inovio Pharmaceuticals Inc.
      • 20.3.10.1 Company Overview
      • 20.3.10.2 Product Portfolio
      • 20.3.10.3 Financials
      • 20.3.10.4 SWOT Analysis
    • 20.3.11 Johnson & Johnson
      • 20.3.11.1 Company Overview
      • 20.3.11.2 Product Portfolio
      • 20.3.11.3 Financials
      • 20.3.11.4 SWOT Analysis
    • 20.3.12 Merck & Co. Inc.
      • 20.3.12.1 Company Overview
      • 20.3.12.2 Product Portfolio
      • 20.3.12.3 Financials
      • 20.3.12.4 SWOT Analysis
    • 20.3.13 Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
      • 20.3.13.1 Company Overview
      • 20.3.13.2 Product Portfolio
      • 20.3.13.3 Financials
      • 20.3.13.4 SWOT Analysis
    • 20.3.14 Novavax Inc.
      • 20.3.14.1 Company Overview
      • 20.3.14.2 Product Portfolio
      • 20.3.14.3 Financials
      • 20.3.14.4 SWOT Analysis
    • 20.3.15 Panacea Biotec Ltd.
      • 20.3.15.1 Company Overview
      • 20.3.15.2 Product Portfolio
    • 20.3.16 Pfizer Inc.
      • 20.3.16.1 Company Overview
      • 20.3.16.2 Product Portfolio
      • 20.3.16.3 Financials
      • 20.3.16.4 SWOT Analysis
    • 20.3.17 Sanofi Pasteur SA (Sanofi SA)
      • 20.3.17.1 Company Overview
      • 20.3.17.2 Product Portfolio
      • 20.3.17.3 Financials
      • 20.3.17.4 SWOT Analysis
    • 20.3.18 Serum Institute of India Pvt. Ltd.
      • 20.3.18.1 Company Overview
      • 20.3.18.2 Product Portfolio
    • 20.3.19 Takeda Pharmaceutical Company Limited
      • 20.3.19.1 Company Overview
      • 20.3.19.2 Product Portfolio
      • 20.3.19.3 Financials
      • 20.3.19.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Vaccine Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Vaccine Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Vaccine Market: Breakup by Patient Type (in %), 2024
  • Figure 6: Global: Vaccine Market: Breakup by Indication (in %), 2024
  • Figure 7: Global: Vaccine Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Vaccine Market: Breakup by Product Type (in %), 2024
  • Figure 9: Global: Vaccine Market: Breakup by Treatment Type (in %), 2024
  • Figure 10: Global: Vaccine Market: Breakup by End User (in %), 2024
  • Figure 11: Global: Vaccine Market: Breakup by Distribution Channel (in %), 2024
  • Figure 12: Global: Vaccine Market: Breakup by Region (in %), 2024
  • Figure 13: Global: Vaccine (Conjugate Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Vaccine (Conjugate Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Vaccine (Inactivated and Subunit Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Vaccine (Inactivated and Subunit Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Vaccine (Live Attenuated Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Vaccine (Live Attenuated Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Vaccine (Recombinant Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Vaccine (Recombinant Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Vaccine (Toxoid Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Vaccine (Toxoid Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Vaccine (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Vaccine (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Vaccine (Paediatric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Vaccine (Paediatric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Vaccine (Adult) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Vaccine (Adult) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Vaccine (Bacterial Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Vaccine (Bacterial Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Vaccine (Meningococcal Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Vaccine (Meningococcal Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Vaccine (Pneumococcal Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Vaccine (Pneumococcal Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Vaccine (Tuberculosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Vaccine (Tuberculosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Vaccine (Haemophilus Influenzae-Hib) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Vaccine (Haemophilus Influenzae-Hib) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Vaccine (Typhoid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Vaccine (Typhoid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Vaccine (Other Bacterial Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Vaccine (Other Bacterial Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Vaccine (Viral Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Vaccine (Viral Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Global: Vaccine (Hepatitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Global: Vaccine (Hepatitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Global: Vaccine (Influenza) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Global: Vaccine (Influenza) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Global: Vaccine (Human Papillomavirus-HPV) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Global: Vaccine (Human Papillomavirus-HPV) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Global: Vaccine (Rotavirus) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Global: Vaccine (Rotavirus) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Global: Vaccine (Herpes Zoster) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Global: Vaccine (Herpes Zoster) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Global: Vaccine (Varicella) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Global: Vaccine (Varicella) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Global: Vaccine (Japanese Encephalitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Global: Vaccine (Japanese Encephalitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Global: Vaccine (Rubella) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Global: Vaccine (Rubella) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Global: Vaccine (Polio) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Global: Vaccine (Polio) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Global: Vaccine (Rabies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Global: Vaccine (Rabies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Global: Vaccine (Dengue) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Global: Vaccine (Dengue) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Vaccine (Other Viral Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Global: Vaccine (Other Viral Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Vaccine (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Global: Vaccine (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Vaccine (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Global: Vaccine (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Vaccine (Multivalent Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Global: Vaccine (Multivalent Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Vaccine (Monovalent Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Global: Vaccine (Monovalent Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Global: Vaccine (Preventive Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Global: Vaccine (Preventive Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Global: Vaccine (Therapeutic Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Global: Vaccine (Therapeutic Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Vaccine (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Global: Vaccine (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Vaccine (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Global: Vaccine (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Global: Vaccine (Vaccination Centres) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Global: Vaccine (Vaccination Centres) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Global: Vaccine (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Global: Vaccine (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 95: Global: Vaccine (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 96: Global: Vaccine (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 97: Global: Vaccine (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 98: Global: Vaccine (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 99: Global: Vaccine (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 100: Global: Vaccine (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 101: Global: Vaccine (Institutional Sales) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 102: Global: Vaccine (Institutional Sales) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 103: Global: Vaccine (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 104: Global: Vaccine (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 105: North America: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 106: North America: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 107: United States: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 108: United States: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 109: Canada: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 110: Canada: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 111: Asia Pacific: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 112: Asia Pacific: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 113: China: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 114: China: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 115: Japan: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 116: Japan: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 117: India: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 118: India: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 119: South Korea: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 120: South Korea: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 121: Australia: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 122: Australia: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 123: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 124: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 125: Europe: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 126: Europe: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 127: Germany: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 128: Germany: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 129: France: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 130: France: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 131: United Kingdom: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 132: United Kingdom: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 133: Italy: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 134: Italy: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 135: Spain: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 136: Spain: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 137: Russia: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 138: Russia: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 139: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 140: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 141: Latin America: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 142: Latin America: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 143: Brazil: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 144: Brazil: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 145: Mexico: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 146: Mexico: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 147: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 148: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 149: Middle East and Africa: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 150: Middle East and Africa: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 151: Turkey: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 152: Turkey: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 153: GCC Countries: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 154: GCC Countries: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 155: Israel: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 156: Israel: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 157: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 158: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 159: Global: Vaccine Industry: SWOT Analysis
  • Figure 160: Global: Vaccine Industry: Value Chain Analysis
  • Figure 161: Global: Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Vaccine Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Vaccine Market Forecast: Breakup by Patient Type (in Million USD), 2025-2033
  • Table 4: Global: Vaccine Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Vaccine Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Vaccine Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 7: Global: Vaccine Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 8: Global: Vaccine Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 9: Global: Vaccine Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 10: Global: Vaccine Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 11: Global: Vaccine Market: Competitive Structure
  • Table 12: Global: Vaccine Market: Key Players